Meplazumab for coronary artery disease
Part of Heart & circulation clinical trials.
This trial tests if meplazumab can help people with chronic coronary syndrome who have stable angina. It focuses on patients with certain fatty deposits around their heart arteries that show up on a special CT scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic coronary syndrome (long-term, stable heart artery disease).
- You have a narrowed artery (at least 50% blocked) that isn't the main problem area.
- Your chest pain (angina) is manageable with medication.
- A CT scan shows a specific type of fatty tissue around the narrowed artery.
- You can follow the study visits and take the medicine as prescribed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special scan to look at the fatty plaque in your arteries can help your doctor decide if you need stronger heart medication to prevent future heart attacks or strokes. If you have moderate blockages and signs of inflammation, you may be able to join.
This trial uses advanced imaging (OCT) and single-cell analysis to study different types of plaque in people with coronary artery disease. It aims to understand how these plaque types differ at a cellular level, which could lead to better treatments.
This trial tests a new drug called Ziltivekimab to see if it can reduce plaque buildup in the heart arteries after a heart attack. It may help prevent future heart problems by targeting inflammation.
This trial uses a heart scan (PET/CT) to better estimate blood flow in people with long-term coronary artery disease. It aims to help doctors choose the best treatment strategy and decide who may need more invasive testing or procedures.
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
This trial studies whether lowering LDL (“bad cholesterol”) with a PCSK-9 inhibitor (evolocumab) improves blood flow to the heart, measured by special PET scans. It’s for people over a certain age who have stable coronary artery disease and a higher risk of heart problems.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.